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ABSTRACT:
3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) is a widely
misused synthetic amphetamine derivative and a serotonergic neu-
rotoxicant in animal models and possibly humans. The underlying
mechanism of neurotoxicity involves the formation of reactive oxygen
species although their source remains unclear. It has been postulated
that MDMA-induced neurotoxicity is mediated via the formation of
bioreactive metabolites. In particular, the primary catechol metabo-
lites, 3,4-dihydroxymethamphetamine (HHMA) and 3,4-dihydroxyam-
phetamine (HHA), subsequently cause the formation of glutathione
and N-acetylcysteine conjugates, which retain the ability to redox
cycle and are serotonergic neurotoxicants in rats. Although the pres-
ence of suchmetabolites has been recently demonstrated in rat brain
microdialysate, their formation in humans has not been reported. The
present study describes the detection of 5-(N-acetylcystein-S-yl)-3,4-
dihydroxymethamphetamine (N-Ac-5-Cys-HHMA) and 5-(N-acetyl-
cystein-S-yl)-3,4-dihydroxyamphetamine (N-Ac-5-Cys-HHA) in hu-
man urine of 15 recreational users of MDMA (1.5 mg/kg) in a
controlled setting. The results reveal that in the first 4 h after MDMA
ingestion 0.002% of the administered dose was recovered as
thioether adducts. Genetic polymorphisms in CYP2D6 and catechol-
O-methyltransferase expression, the combination of which are major
determinants of steady-state levels of HHMA and 4-hydroxy-3-me-
thoxyamphetamine, probably explain the interindividual variability
seen in the recovery of N-Ac-5-Cys-HHMA and N-Ac-5-Cys-HHA. In
summary, the formation of neurotoxic thioether adducts of MDMA
has been demonstrated for the first time in humans. The findings lend
weight to the hypothesis that the bioactivation of MDMA to neuro-
toxic metabolites is a relevant pathway to neurotoxicity in humans.
3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) is a psy-
chostimulant widely abused among young people. MDMA exhibits
distinct pharmacological properties, collectively described as entac-
togenic, which differentiate it from classic amphetamines (Nichols,
1986). MDMA produces acute and long-term serotonergic neurotox-
icity in rodents, primates, and, possibly, in humans, with the severity
of toxicity dependent on the dose and frequency of administration
(Green et al., 2003). Such neurotoxicity is demonstrated by a decrease
in tryptophan hydroxylase activity (Stone et al., 1988), a reduction in
serotonin content, a dose-dependent persistent decrease in the number
of 5-HT transporter sites and 5-HT receptors in several regions of the
brain (Aguirre et al., 1995; Ricaurte et al., 2000), and an impairment
of central 5-HT function (Barrionuevo et al., 2000).
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Oxidative stress, hyperthermia, excitotoxicity, and various apo-
ptotic pathways have been invoked as the underlying mechanism(s)
of MDMA-induced neurotoxicity (Cadet et al., 2007). With respect
to oxidative stress, various sources of reactive oxygen species
have been suggested, including the monoamine oxidase-mediated
metabolism of tyrosine/dopamine, which generates hydrogen per-
oxide as a by-product, and the oxidative metabolism of MDMA
to redox active catechols. However, until recently, evidence sup-
porting a link between MDMA metabolism and neurotoxicity has
been primarily indirect (Monks et al., 2004; Jones et al., 2005).
MDMA is metabolized via cytochrome P450-mediated N-demeth-
ylation to the active metabolite 3,4-methylenedioxyamphetamine
(MDA). MDMA and MDA are both O-demethylenated, again
via cytochrome P450, to 3,4-dihydroxymethamphetamine (HHMA,
N-methyl--methyldopamine) and 3,4-dihydroxyamphetamine
(HHA, -methyldopamine), respectively (Fig. 1) (Maurer et al.,
2000; de la Torre et al., 2004). Because HHMA and HHA are both
catechols, they can undergo further autooxidation to the corre-
sponding ortho-quinones, which are readily conjugated with glu-
tathione (GSH) to form glutathionyl adducts (Hiramatsu et al.,
1990). The GSH adducts of HHMA and HMA appear to be
transported into the brain via blood-brain barrier GSH transporters,
where they are subsequently metabolized to the corresponding
N-acetylcysteine (NAC) adducts (Bai et al., 2001). Direct injection
of the GSH and N-acetylcysteine conjugates of HHMA or HMA
into rat brain produces not only the acute neurobehavioral effects
of the parent drug but also its selective serotonergic neurotoxicity
(Miller et al., 1996; Bai et al., 1999). Moreover, because multidose
administration of MDMA is typical of drug intake during rave
parties, the effects of multiple doses of MDMA on the concentra-
tion of catechol-thioether metabolites in rat brain were determined.
The data revealed that thioether metabolites, especially the NAC
conjugates, accumulate in rat brain after multidose administration
of MDMA (Erives et al., 2008). The ability of these metabolites to
generate reactive oxygen species and to arylate proteins, in com-
bination with their ability to modulate the activity of proteins
involved in the regulation of neurotransmitter transport (Jones et
al., 2004), suggests that they play an important role in the devel-
opment of MDMA-mediated serotonergic neurotoxicity.
Although catechol-thioether metabolites of MDMA have been
identified in rat brain (Jones et al., 2005), there is no evidence for their
formation in humans after MDMA exposure. GSH adducts are me-
tabolized by -glutamyl transpeptidase and subsequently by amino-
peptidase M to the corresponding cysteine conjugates, which are
ultimately N-acetylated to form the N-acetylcysteine derivative (also
referred to as mercapturic acid). In humans, a noninvasive approach to
demonstrate the formation of GSH adducts of HHMA and HHA after
MDMA exposure would be the detection of the mercapturate deriv-
atives in urine. In the present study, an analytical methodology for the
detection of MDMA-derived mercapturates in human urine has been
developed and applied to samples obtained from recreational users of
MDMA (1.5 mg/kg, 75–100 mg dose) in a controlled setting. Finally,
because enzymes regulating the formation (CYP2D6) and the inacti-
vation (COMT) of catechol metabolites of MDMA in humans are
highly polymorphic, the contribution of genetic variability to interin-
dividual differences in the urinary concentration of mercapturates has
also been examined.
FIG. 1. Pathways involved in the metabolic disposition of MDMA in humans (information obtained in part from Maurer et al., 2000). Major pathways are outlined with
thicker lines.
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Materials and Methods
Chemicals and Reagents. Ultrapure water was obtained using a Milli-Q
purification system (Millipore, Molsheim, France). HPLC-grade acetonitrile,
methanol, hydrochloric acid, sodium acetate, potassium hydrogen phosphate,
potassium dihydrogen phosphate, sodium hydroxide, trifluoroacetic acid, met-
abisulfite, dithiothreitol (DTT), formic acid, ammonia, ammonium formate,
and ammonium chloride were obtained from Merck (Darmstadt, Germany).
EDTA, N-acetyl-L-cysteine, and mushroom tyrosinase (2033 U/mg) were
obtained from Sigma-Aldrich (St. Louis, MO). N-Acetyl-L-cysteine methyl
ester was obtained from Fluka Biochemika (Riedel-de Hae¨n, Seelze, Ger-
many). Bond Elut PBA [phenylboronic acid (PBA), 500 mg of sorbent]
columns were purchased from Varian, Inc. (Harbor City, CA) and mounted on
a Vac Elut vacuum manifold (Supelco, Bellefonte, PA).
Synthesis of N-Acetylcysteine and N-Acetylcysteine-Methyl Ester
Adducts of HHMA and HHA. 5-(N-Acetylcystein-S-yl)-3,4-dihydroxymeth-
amphetamine-HHMA (N-Ac-5-Cys-HHMA), 5-(N-acetylcystein-S-yl)-3,4-di-
hydroxyamphetamine-HHA (N-Ac-5-Cys-HHA), and 5-(N-acetylcystein-S-
yl)-methylesther-3,4-dihydroxymethamphetamine [N-Ac-5-Cys-O-Me-HHMA,
as internal standard (IS)] were synthesized following an experimental proce-
dure similar to that described previously (Jones et al., 2005). In brief, 3 mM
HHMA or HHA, 8 mM N-acetyl-L-cysteine or N-acetyl-L-cysteine methyl
ester, and 1016 IU of tyrosinase from mushroom (2033 U/mg) in 100 ml of
phosphate buffer (50 mM), pH 7.4, previously degassed with argon were
incubated for 30 min at room temperature. The reaction was quenched with 2
ml of 88% formic acid. The reaction mixture was concentrated by lyophiliza-
tion, and adducts were isolated by semipreparative reverse-phase HPLC-UV
(conditions described under Analytical HPLC-UV and Semipreparative HPLC-
UV). Collected fractions were lyophilized, and the structure and purity of the
compound were determined by NMR and high-performance liquid chroma-
tography coupled to tandem mass spectrometry (HPLC-MS/MS). HPLC-
MS/MS revealed a single compound with a molecular ion corresponding to
each product synthesized: N-Ac-5-Cys-HHA (m/z 329), N-Ac-5-Cys-HHMA
(m/z 343), and N-Ac-5-Cys-O-Me-HHA (m/z 357). The molecular ion, once
further fragmented, gives rise to several daughter ions, including those of
N-acetylcysteine (m/z 161.9), N-acetylcysteine methyl ester (m/z 175.9),
HHMA (m/z 182.9), and HHA (m/z 168.9).
Working Standards. Solutions of 1 mg/ml N-Ac-5-Cys-HHMA, N-Ac-5-
Cys-HHA, and N-Ac-5-Cys-O-Me-HHMA (IS) were prepared in methanol.
Working solutions of 0.1, 1, 10, and 100 g/ml of each compound were
prepared by dilution of the corresponding 1 mg/ml stock solution.
Preparation of Calibration and Quality Control Samples. Calibration
curves and QC samples were prepared by adding appropriate volumes of
working solutions to test tubes, each containing 5 ml of drug-free urine. QC
samples were prepared with solutions different from those used for the prep-
aration of calibration curves. Final concentrations in the calibration curves
were 4, 7, 15, 20, and 30 ng/ml N-Ac-5-Cys-HHMA and N-Ac-5-Cys-HHA.
Control urine samples containing appropriate analytes at different concentra-
tions were prepared in drug-free samples in 5-ml aliquots. The concentrations
of QC samples were as follows: 4, 12, and 26 ng/ml of both metabolites.
1H NMR spectra were obtained in deuterated methanol solutions on
Varian ANOVA 500 and Unity 300 spectrometers. Chemical shifts are
reported in parts per million relative to the multiplet at 3.39 ppm of
deuterated methanol.
Analytical HPLC-UV. A LaChrom Pump L-7100 (Hitachi and Merck)
with a manual injector coupled to a UV LC-75 spectrophotometric detector
(PerkinElmer Life and Analytical Sciences, Waltham, MA) was used, with a
Lichrosphere RP-18 5 m (4  250 mm) column. The HPLC solvent system
was a gradient and consisted of two phases: A, 0.1% TFA in water; and B, 20%
water-80% acetonitrile with 0.095% TFA. The step linear gradient for elution
was from 0% B to 5% B in 1 min and from 5% B to 60% B in 30 min with
a flow rate 1 ml/min, and the eluate was monitored at 215 nm.
Semipreparative HPLC-UV. A Waters LC 4000 HPLC system (Waters,
Milford, MA) coupled to an UV 4000 Series Spectrophotometric Detector
(Hitachi and Merck) was used with a X-Terra MS C18 column (10 m, 19 
250 mm). The same mobile phases and gradient as those described for the
analytical HPLC-UV system were used for semipreparative HPLC but with a
flow rate of 12 ml/min.
HPLC-MS/MS. Extracted urine samples were analyzed in a Micromass
Quattro micro API triple quadrupole mass spectrometer (Waters, Etten-Leur,
The Netherlands) equipped with an electrospray ionization (ESI) probe cou-
pled to an Alliance HPLC system (Waters). An Atlantis T3 3 m (2.1  20
mm) column (Waters) was used. The mobile phase flow rate was 0.25 ml/min.
A binary mobile phase was used: A, 100% 0.1% formic acid in water; and B,
100% acetonitrile. The linear gradient for elution was 0 to 10% B in 15 min.
The ESI probe was operated in positive mode, and the ESI settings were as
follows: capillary voltage, 3000 V; source temperature, 120°C; desolvation
temperature, 420°C; cone voltage, 20 V; and cone gas and desolvation gas flow
rates, 34 and 609 l/h, respectively. Initial screening of the samples was
performed in positive mode in the first quadrupole based on full MS measure-
ments between 50 and 500 m/z only (Q1 MS mode). After the Q1 MS scan,
selected reactions monitoring was performed. The fragmentation channels
monitored for [M  H] to product ions were for N-Ac-5-Cys-HHMA
m/z 343 3 130, m/z 343 3 181, m/z 343 3 207, and m/z 343 3 130; for
N-Ac-5-Cys-HHA m/z 329 3 130, m/z 329 3 and 207, and m/z 329 3 270;
and for N-Ac-5-Cys-O-Me-HHMA (IS) m/z 357 3 144, m/z 357 3 181, and
m/z 3573 207. The maximum ionization time for each product ion scan was
2 s with an isolation width of 0.9 m/z. Quantitative analysis was based on peak
area ratios of the 343 and 329 atomic mass unit ions relative to the internal
standard ion at 357 atomic mass units. On each day of analysis, a 5-point
calibration curve ranging from 3 to 30 ng/ml was performed in duplicate.
Genotyping. Samples of 1 ml of whole blood were taken for DNA extraction
and CYP2D6 genotyping (DrugMEt; Jurilab Ltd., Kuopio, Finland). The follow-
ing allelic variants were determined: *1, *2, *4, *5, *9, *10, *35, and *41. In
addition, deletions (*3) and gene duplications (*1xn and *2xn) were determined.
The COMT Val/Met (rs4680) and P2 promoter (rs2097603) allelic variants
were determined using the 5 exonuclease TaqMan assay performed using an
ABI 7900HT Sequence Detection System (real-time polymerase chain reac-
tion) supplied by Applied Biosystems (Foster City, CA). Primers and fluores-
cent probes for the Val/Met assay were obtained from Applied Biosystems by
submission of the polymorphic sequence of the COMT gene to Assay-by-
Design Service (p/n 4332728, COMT_V158MS1AG). According to assay
design the primers have the following sequences: forward 5-CCCAGCG-
GATGGTGGAT-3 and reverse 5-CAGGCATGCACACCTTGTC-3. The
reporter probes for the real-time polymerase chain reaction have the following
sequences: FAM-TCGCTGGCGTGAAG-3 and VICTTCGCTGGCAT-
GAAG-3. For the P2 promoter assay, primers have the following sequences
according to those published previously (Chen et al., 2004): forward 5-
GCCGTGTCTGGACTGTGAGT-3 and reverse 5-GGGTTCAGAAT-
CACGGATGTG-3. The reporter probes have the following sequences:
6FAMAACAGACAGAAAAGTTTCCCCTTCCCA-3 and VICCAGACA-
GAAAAGCTTCCCCTTCCCATA-3. Reaction conditions were those de-
scribed in the ABI PRISM 7900HT User’s Guide. Endpoint fluorescent signals
were detected on the ABI 7900 system, and the data were analyzed using the
Sequence Detector System software, version 2.1.
Subjects and Dosing. The study was conducted in accordance with the
Declaration of Helsinki (2000), approved by the local institutional review
board (Clinical Research Ethical Committee of the Municipal Institute of
Health Care), and authorized by the Spanish Medicines Agency of the Spanish
Ministry of Health. All subjects gave their written informed consent before
inclusion in the study and were compensated for their participation.
Each subject was interviewed by a physician to exclude concomitant
medical conditions and underwent a general physical examination, routine
laboratory tests, urinalysis, and 12-lead electrocardiogram. Subjects were
interviewed by a psychiatrist (Psychiatric Research Interview for Substance
and Mental Disorders for DSM-IV) to exclude those with a history of or
actual major psychiatric disorders (schizophrenia, psychosis, and major
affective disorder). Fifteen individuals (11 males and 4 females) fulfilled
the inclusion criteria and had a mean age of 26 years (range 19 –33 years),
mean body weight of 69.6 kg (range 54.2–91.2 kg), and mean height of 181
cm (range 171–196 cm). Subjects reported an average of 26 previous
experiences (range 6 –100 previous experiences) with MDMA. All but four
were current smokers. None met the criteria of abuse or drug dependence
(except for nicotine dependence). All had previous experience with other
psychostimulants, cannabis, or hallucinogens. None had a history of ad-
verse medical or psychiatric reactions after MDMA consumption. The
1450 PERFETTI ET AL.
subjects were phenotyped with dextromethorphan for CYP2D6 enzyme
activity, and all were categorized as extensive metabolizers (Schmid et al.,
1985). All subjects received a single 1.5 mg/kg dose of MDMA. MDMA
was obtained from the Spanish Ministry of Health, and MDMA soft gelatin
capsules were prepared and supplied by the Department of Pharmacy of
Hospital del Mar (Barcelona, Spain).
Sample Collection. Plasma samples were collected at 0, 0.3, 0.6, 1, 1.5, 2,
and 4 h after MDMA administration. Urine samples were collected before and
after drug administration at the 0 and 0 to 4 h time period. Urine was collected
in refrigerated plastic containers covered with aluminum foil to prevent light
exposure. Samples were immediately acidified with 0.5 ml of 6 M HCl,
distributed in aliquots, and stored at 20°C until further analysis. Concentra-
tions of MDMA and metabolites in plasma and urine were determined by gas
chromatography coupled to mass spectrometry after an analytical procedure
described previously (Pizarro et al., 2002).
Preparation of Urine Sample for the Analysis of N-Acetyl-Cysteinyl
Adducts. For the determination of N-Ac-5-Cys-HHMA and N-Ac-5-Cys-
HHA, 5 ml of urine and 25 l of the appropriate IS solution were transferred
into 15-ml screw-capped glass tubes. Urine pH was adjusted to 9.5 with
ammonium chloride buffer (pH 9.5). After vortex mixing, the sample was
filtered through a 0.22-m centrifuge filter at 3500 rpm for 5 min. Bond Elut
PBA (500-mg) columns were conditioned by washing with 5 ml of ammonium
chloride buffer (pH 9.5). Urine samples were applied to the column and forced
to pass through. After application of the sample, the column was washed twice
with 3 ml of H2O/MeOH (95:5%). Analytes were then eluted with 2 ml of
TFA-1 M/MeOH (30:70%) and 20 mM DTT. The eluate was evaporated for 20
min under a stream of nitrogen in a water bath at 39°C to evaporate the
methanol and then frozen and lyophilized. The dried extract was reconstituted
in 100 l of the mobile phase with 9 mM Na2S2O5 and 5 mM EDTA as
preservatives, transferred to a 0.22-m centrifuge tube and centrifuged at
15,000 rpm for 5 min. The supernatant was then transferred into 200-l
injection vials, and a 40-l aliquot was injected into the LC-ESI-MS/MS
system.
Validation Procedure. Validation of the method was performed according
to a 4-day protocol. Linearity was determined by checking different calibration
curves (n  10 in 4 consecutive days) at five different concentrations of
N-Ac-5-Cys-HHMA (4, 7, 15, 20, and 30 ng/ml) and N-Ac-5-Cys-HHA (4, 7,
15, 20, and 30 ng/ml). Peak area ratios between N-Ac-5-Cys-HHMA or
N-Ac-5-Cys-HHA and the internal standard (N-Ac-5-Cys-O-Me-HHMA) were
used for calculations. A weighted (1/concentration) least-squares regression
analysis was used (SPSS computer software package, version 12.0 for Win-
dows; SPSS Inc., Chicago, IL). By quantifying a quadruplicate of the lower
concentration of the calibration curves, we estimated the limits of detection and
quantification as 3 and 10 standard deviations of the calculated concentrations,
respectively. Intermediate precision was calculated with the relative S.D. of
concentrations calculated for quality control samples (5, 12, and 26 ng/ml
N-Ac-5-Cys-HHMA or N-Ac-5-Cys-HHA), and the interassay accuracy was
the relative error of the calculated concentrations. Five replicates at three
different concentrations of N-Ac-5-Cys-HHMA or N-Ac-5-Cys-HHA (4, 7, 15,
20, and 30 ng/ml) spiked in blank urine were used for the determination of
intra-assay precision (expressed as coefficient of variation for specific added
target concentrations) and accuracy (expressed as percentage error of concen-
tration found as compared with target added concentrations). Interday preci-
sion and accuracy were determined on 3 different experimental days. Analyt-
ical recoveries were calculated by comparison between peak areas of the
calibration samples analyzed with the normal procedure and those obtained
after the same amounts of reference substances and IS were added to blank
urine after extraction. Recoveries were analyzed at three different concentra-
tions (4, 15, and 30 ng/ml) using four replicates for each concentration
evaluated. The stability of N-Ac-5-Cys-HHMA and N-Ac-5-Cys-HHA in urine
was evaluated in two freeze/thaw cycles. The test involved a comparison of
replicate stability samples, which had been frozen and thawed two times with
a fresh urine sample that had not been frozen.
Results
Sample Preparation. Because the catecholamine-like properties of
HHMA and HHA conjugates makes them very unstable and sensitive
to oxidation and decomposition, the whole process from sample
collection to HPLC-MS/MS determination was performed as quickly
as possible, keeping samples cold and protected from light during the
entire procedure. Moreover, addition of preservatives was necessary
to prevent oxidation. More precisely, EDTA prevents catalytic oxi-
dation by metal ions, whereas sodium metabisulfite acts as a reducing
agent. Because these two preservatives interfere with our solid-phase
extraction process, we used 20 mM DTT as a preservative during the
extraction and added EDTA and sodium metabisulfite to the samples
after the extraction to further protect the analytes from oxidation
during the remainder of the analysis.
PBA has proven to be especially effective in the isolation of
catecholamines from biological fluids because boronate groups have a
high specificity for cis-diol-containing compounds such as catechols.
We chose Varian Bond Elut PBA columns for solid-phase extraction;
these columns are packed with phenylboronic acid covalently linked
to a silica gel surface. The specificity of this sample preparation
method is based on the difference in affinity for PBA between the
catecholamines and potentially interfering compounds present in the
sample matrix.
LC-MS/MS Analysis. The analytes were separated on an Atlantis
T3 column that produces good separation of small polar compounds
with good retention and selectivity. Quantitation by ESI-MS was
performed in multiple reaction monitoring (MRM) mode to enhance
sensitivity and precision; three fragment ions of high abundance were
used for the detection of each compound. The full-scan MS/MS
spectra as well as the proposed fragmentation patterns for N-Ac-5-
FIG. 2. Full-scan MS/MS spectra and the proposed patterns of fragmentation for
N-Ac-5-Cys-HHMA (A), N-Ac-5-Cys-O-Me-HHMA (B) (IS), and N-Ac-5-Cys-
HHA (C). Fragment ions used for detection and quantification of each compound
are highlighted in gray.
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Cys-HHMA, N-Ac-5-Cys-HHA, and N-Ac-5-Cys-O-Me-HHMA are
shown in Fig. 2. A representative MRM chromatogram of the second
lowest calibrator sample (7 ng/ml N-Ac-5-Cys-HHMA and N-Ac-5-
Cys-HHA and 5 ng/ml IS) is shown in Fig. 3. Quantitation was
performed by comparison of peak area ratio (analyte versus IS) with
calibration curves obtained with spiked calibrators. We used the
methyl ester analog of N-Ac-5-Cys-HHMA (N-Ac-5-Cys-O-Me-
HHMA) as the IS for both the HHMA and HHA adducts because
these two compounds are structurally very similar and adding the
methyl ester analog of N-Ac-5-Cys-HHA as an IS would only add
more complexity to the separation of these structurally similar com-
pounds, without improving quantitation.
Method Validation. Standard curve plots for the analytes were
linear in the range of tested concentrations (4–30 ng/ml). Intra- and
interassay accuracy and precision results satisfactorily met current
acceptance criteria in the validation of bioanalytical methods (see
Supplemental Data). Analytical recoveries (80.5% for N-Ac-5-Cys-
HMA and 90.5% for N-Ac-5-Cys-HHMA) and calculated limits of
detection and quantification (1.5 and 4.3 ng/ml N-Ac-5-Cys-HHA and
4.3 and 12.9 ng/ml N-Ac-5-Cys-HHMA) were considered adequate
for the purpose of the study. The freeze/thaw stability test showed that
neither N-Ac-5-Cys-HHMA nor N-Ac-5-Cys-HHA was stable in
urine during freeze/thaw cycles (data not shown).
Analysis of N-Ac-5-Cys-HHMA and N-Ac-5-Cys-HHA in
Human Urine After MDMA Consumption. The optimized LC-
MS/MS analysis was applied to urine samples from healthy recre-
ational users of MDMA, who were given a single 1.5 mg/kg oral dose
of MDMA. Urine samples were collected before and after drug
administration at the 0 and 0 to 4 h time period. Figure 4 shows MRM
chromatograms of urine from a volunteer before (t  0) and 0 to 4 h
after MDMA intake. Estimated adduct concentrations for this volun-
teer were 2.1 and 7.2 ng/ml for N-Ac-5-Cys-HHA and N-Ac-5-Cys-
HHMA, respectively.
MDMA, MDA, HMMA, and HMA were also determined in urine.
Tables 1 and 2 and Fig. 5 summarize urinary excretion of MDMA and
its metabolites, including the thioether adducts of HHMA and HHA.
There is a significant correlation between N-Ac-5-Cys-HHMA re-
covered in urine and the composite parameters MDMA-HMMA (ratio
of urinary recoveries, 0–4 h, r  0727, p  0.003, n  14) (Fig.
5A) and MDA-HMA (ratio of urinary recoveries, 0–4 h, r  0569,
p  0.034, n  14) but not with MDMA or HMMA taken alone. The
recovery of N-Ac-5-Cys-HHMA was related marginally to the
CYP2D6 score (p  0.1) (Fig. 5C) and to the COMT genotype (p 
0.1) (Fig. 5B) of subjects. The recovery of N-Ac-5-Cys-HHMA was
2-fold higher among met/met subjects compared with the value for the
val/val subjects (0.091  0.005 versus 0.041  0.003 mol/4 h, n 
4 for each genotype). A similar trend was observed for MDMA-
HMMA and COMT genotype.
Discussion
We have, for the first time in humans, identified and quantified
catechol-thioether metabolites of MDMA (N-Ac-5-Cys-HHMA and
N-Ac-5-Cys-HHA). The identification of MDMA mercapturates lends
credence to the hypothesis that the metabolic bioactivation of MDMA
has the potential to contribute to MDMA neurotoxicity in humans.
Preliminary data on polymorphisms of genes involved in the metab-
olism of MDMA reveal that specific genotypic profiles may constitute
risk factors for the development of neurotoxicity.
The fraction of the MDMA dose recovered as thioether adducts
excreted in urine 4 h after MDMA ingestion is 0.002%. Approxi-
mately 1.6% of a dose of MDA (23 mol s.c.) is excreted in bile as
5-(glutathion-S-yl)--methyldopamine within 5 h. This translates to
50% of the dose of MDA that causes both neurobehavioral and
neurochemical changes (Miller et al., 1996). Moreover, because poly-
phenolic-GSH conjugates and the corresponding cysteine and NAC
FIG. 4. LC-MS/MS chromatograms of urine samples from a volunteer before
MDMA intake (t  0) (A), and a 0 to 4 h sample from a volunteer ingesting 80 mg
of (R,S)-MDMA (B).
FIG. 3. LC-MS/MS chromatograms of blank human urine (A) and human urine
spiked with N-Ac-5-Cys-HHMA and N-Ac-5-Cys-HHA (B), 7 ng/ml each, and 5
ng/ml of IS.
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conjugates are biologically reactive, quantitation of their biliary and
urinary excretion probably represents a minimum estimate of in vivo
formation. Indeed, after administration of 2-hydroxy-1-(glutathion-S-
yl)-17-estradiol to rats, only 15% of the dose was recovered in urine
and 5% in feces, several days after administration (Elce, 1972), and up
to 96% of an infused dose of polyphenolic-GSH conjugates is retained
in the animal in the in situ perfused rat kidney model (Hill et al., 1994;
Rivera et al., 1994). These findings emphasize that quantitation of
N-Ac-5-Cys-HHMA and N-Ac-5-Cys-HHA in urine probably under-
estimates the contribution of this metabolic pathway to MDMA dis-
position. It is also relevant to note that these metabolites are extremely
potent serotonergic toxicants (Miller et al., 1997; Bai et al., 1999;
Jones et al., 2005). As little as 7 nmol of N-Ac-5-Cys-HHMA is
sufficient to produce decreases in striatal and cortical 5-HT concen-
trations when injected directly into the brain (Jones et al., 2005).
Finally, multiple doses of MDMA result in the accumulation of
N-Ac-5-Cys-HHMA and N-Ac-5-Cys-HHA in rat brain (Erives et al.,
2008). Thus, the fraction of MDMA excreted in urine needs to be
considered in the context of the fraction of MDMA converted to
N-Ac-5-Cys-HHMA and N-Ac-5-Cys-HHA in vivo, in combination
with the neurotoxic potency of these metabolites.
The 0 to 4 h time period for the collection of urine samples was
selected on the premise that CYP2D6 would remain active during this
time period and before complete inactivation. The low urinary recov-
ery during the first 4 h after ingestion could also be explained by the
accumulation of these metabolites in the brain, as shown in rats
(Erives et al., 2008), and by the fact that the kinetics of mercapturate
formation and excretion is unknown, with larger recoveries possible
over extended urine collection periods.
The fraction of the catechol metabolites converted to neurotoxic
metabolites varies greatly between individuals exposed to similar
doses of MDMA (Tables 1 and 2). This finding is somewhat expected,
because the enzymes that participate in the formation (CYP2D6) and
inactivation (COMT) of HHMA and HMA are highly polymorphic in
the human population (de la Torre and Farre´, 2004). There is a
significant correlation between N-Ac-5-Cys-HHMA recovered in
urine and the ratio of MDMA/HMMA but not with MDMA or HHMA
taken alone. Again, this is not unexpected because the formation of
the N-Ac-5-Cys adduct depends on the availability of the intermediary
catechol metabolite, which in turn is to some extent a balance between
its generation via O-demethylenation of MDMA (CYP2D6) and its
removal via COMT-mediated O-methylation to HMMA. In concor-
dance with this view, the recovery of N-Ac-5-Cys-HHMA is also
moderately correlated to the CYP2D6 score and the COMT genotype
of subjects (p  0.1). All of the subjects exhibited the same CYP2D6
phenotype (extensive metabolizers). The extensive metabolizer phe-
notype is explained by the combination of several allelic variants
displaying different degrees of functionality (Tables 1 and 2; Fig. 5C).
In the present study the relevance of the CYP2D6 genetic polymor-
phism on N-Ac-5-Cys adduct formation can only be partially delin-
eated on the basis of different activity rates within each particular
genotype. It would be necessary to include more extreme phenotypes
(poor metabolizers and ultra-rapid metabolizers) to fully assess the
contribution of the CYP2D6 polymorphism to N-Ac-5-Cys adduct
formation. However, the effect of genetic polymorphisms in CYP2D6
on thioether catechol adduct formation and subsequent neurotoxicity
is likely to be moderate and possibly only relevant during the first
hours after MDMA ingestion because the majority of hepatic
TABLE 1
Urinary excretion of MDMA and its metabolites (males)
Volunteer Code CYP2D6 Genotype MDMA Dose
Excreted 0 to 4 h (Males)
MDMA MDA HMMA HMA N-Ac-5-Cys-HHMA N-Ac-5-Cys-HHA Total
mg mg/kg mol
11 *1/*4 90 1.4 33.7 0.94 9.9 1.13 0.0016 0.0002 45.64
12 *1/*10 80 1.5 12.8 0.65 12.3 1.11 0.0041 ND 26.88
13 *1/*2 100 1.4 9.4 0.75 26.3 1.50 0.0062 ND 37.88
14 *1/*9 100 1.1 4.5 0.37 6.2 0.77 0.0163 0.0040 11.84
15 *2/*41 90 1.5 9.7 0.76 7.1 1.44 ND 0.0012 19.08
16 *1/*2 100 1.4 3.3 0.58 19.9 1.30 0.0102 0.0025 25.16
18 *9/*10 100 1.2 2.7 0.30 2.9 0.52 0.0022 0.0017 6.43
20 *2/*4 100 1.4 25.1 0.67 11.5 0.51 0.0010 0.0004 37.85
21 *1/*2 100 1.5 10.9 0.50 16.5 0.95 0.0160 0.0036 28.85
22 *1/*2 100 1.5 45.2 2.25 9.8 1.70 0.0012 0.0028 58.91
23 *1/*2 80 1.4 68.3 3.04 16.8 3.52 0.0031 0.0055 91.67
Mean 20.5 0.98 12.7 1.31 0.0062 0.0024 35.47
S.D. 6.3 0.25 2.0 0.24 0.0018 0.0005 7.21
Recovery as % of dose 4.0 0.19 2.5 0.25 0.0012 0.0005 6.94
ND, not detected.
TABLE 2
Urinary excretion of MDMA and its metabolites (females)
Volunteer Code CYP2D6 Genotype MDMA Dose
Excreted 0–4 h (Females)
MDMA MDA HMMA HMA N-Ac-5-Cys-HHMA N-Ac-5-Cys-HHA Total
mg mg/kg mol
17 *2/*10 80 1.3 46.4 1.64 16.34 0.9 0.0042 0.0013 65.36
19 *1/*2 75 1.5 19.7 0.96 32.93 1.8 0.0088 0.0018 55.41
26 *1/*10 75 1.5 15.5 1.35 38.92 2.2 0.0049 0.0015 58.03
27 *1/*35 75 1.4 7.9 0.49 16.86 1.1 0.0091 0.0019 26.39
Mean 22.4 1.11 26.26 1.5 0.0070 0.0020 51.30
S.D. 8.4 0.25 5.71 0.3 0.0013 0.0001 8.57
Recovery as % of dose 4.3 0.21 5.07 0.3 0.0013 0.0003 9.88
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CYP2D6 is inactivated within 1 h after a recreational dose of MDMA
(Yang et al., 2006; O’Mathu´na et al., 2008) and because when
CYP2D6 is inhibited before MDMA intake with paroxetine, a potent
mechanism-based inactivator of this enzyme (Bertelsen et al., 2003),
only a 30% increase of the area under the curve of MDMA in plasma
is observed (Segura et al., 2005). Prolonging the urine collection after
MDMA intake would assist in assessing the correlation (or lack
thereof) between CYP2D6 polymorphism and N-Ac-5-Cys adduct
formation.
Considering that the pattern of MDMA consumption often involves
repeated doses and that CYP2D6 MDMA-induced inactivation gives
rise to a phenomenon of phenocopying, which converts subjects
toward a poorer metabolizer phenotype, independent of their original
genotype (O’Mathu´na et al., 2008), we would expect genetic poly-
morphisms and activity of COMT to be a more important determinant
of NAC adduct formation and of susceptibility to MDMA-mediated
neurotoxicity. Consistent with this view, administration of the COMT
inhibitor entacapone 30 min before MDMA dosing to rats exacerbates
the 5-HT depletion produced by MDMA, an effect not related either
to changes on core body temperature, because the MDMA-induced
hyperthermic response was not significantly altered, or to the serum
L-tyrosine levels, which where higher in the MDMA-treated rats than
inn the MDMA/entacapone-treated rats, suggesting that toxic MDMA
catechol metabolites are responsible for the MDMA toxicity in the
entacapone-treated rats (Gon˜i-Allo et al., 2008a). Moreover, although
the HMMA and HMA plasma concentrations were significantly lower
in the entacapone-treated animals, plasma concentrations of HHMA
and HHA were unchanged, suggesting that these compounds are
cleared by alternative pathways (Gon˜i-Allo et al., 2008b), for exam-
ple, thioether adduct formation. Taken together, these results support
the idea that the COMT activity level may be relevant in terms of
susceptibility to MDMA neurotoxicity.
The observed gender differences in the urinary excretion of MDMA
and its metabolites can be partly explained by the more rapid renal
process in males, including clearance of drugs metabolized by
CYP2D6 (Schwartz, 2003). More studies with female subjects are
needed to draw any further conclusions on gender differences in
MDMA metabolism. The urinary excretion of the catechols HHMA
and HHA needs to be estimated to determine whether there are gender
differences in the fraction of these metabolites that are converted to
thioether adducts.
In summary, we report the first published data on the urinary
excretion of catechol-thioether metabolites of MDMA. The neurotox-
icity of these metabolites is well established in rats. Because the
metabolic pathways of MDMA in humans are similar to those in rats,
with differences only in the relative kinetics of metabolism (de la
Torre and Farre´, 2004), it is likely that these metabolites are also
present in human brain with the potential to achieve neurotoxic
concentrations. The dose administrated in this study (1.5 mg/kg,
75–100 mg) represents a typical recreational single dose (Parrott,
2002). Although it is not well established whether a single recreational
dose is likely to produce long-term serotonergic deficits in humans, it
can be expected that multiple or regular use of MDMA in humans (the
typical pattern of MDMA consumption) may lead to long-term sero-
tonergic damage similar to that seen in animal studies. Thus, catechol-
thioether metabolites of MDMA may contribute to MDMA neurotox-
icity in humans. Factors that influence interindividual differences in
the formation of these adducts will be major determinants of the
susceptibility of humans to MDMA neurotoxicity. In this respect,
although much attention has been focused on the CYP2D6 polymor-
phism with respect to the generation of thioether adducts and neuro-
toxicity, polymorphisms in COMT seem to be more relevant. A more
detailed examination of the influence of COMT polymorphism on
NAC adduct formation is warranted. An assessment of thioether
adducts in human plasma would assist in understanding their phar-
macokinetics, which would also be of relevance to the possible
prediction of a neurotoxic response, especially in view of the fact that
a critical threshold concentration of neurotoxic metabolites seems to
be necessary to produce a permanent neurotoxic effect (Jones et al.,
FIG. 5. The relationship of COMT genotypes with the ratio MDMA vs. HMMA (A)
and of COMT genotypes (B) and CYP2D6 scores (C) with urinary N-Ac-5-Cys-HHMA
excretion. Cytochrome P450 (CYP) score 1, subjects heterozygous for a wild-type allele
(*1 or *2) and a nonfunctional allele (*4); CYP score 2, subjects bearing alleles partially
functional (*9, *10, or *41); CYP score 3, homozygous wild type (*1, *2, or *35). Bars
show means. Error bars show mean  1.0 S.E.
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2005). The extent of metabolic bioactivation, modulated by environ-
mental and genetic factors, may be a major contributing factor to
susceptibility to MDMA neurotoxicity.
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